雖然這篇Nct04325061鄉民發文沒有被收入到精華區：在Nct04325061這個話題中，我們另外找到其它相關的精選爆讚文章
[爆卦]Nct04325061是什麼？優點缺點精華區懶人包
你可能也想看看
搜尋相關網站
-
#1Efficacy of Dexamethasone Treatment for Patients With ARDS ...
ClinicalTrials.gov Identifier: NCT04325061. Recruitment Status : Terminated (Lack of enrollment). First Posted : March 27, 2020.
-
#2study protocol for a randomized controlled superiority trial
ClinicalTrials.gov NCT04325061 . Registered on 25 March 2020 as DEXA-COVID19.
-
#3NCT04325061 - Cochrane COVID-19 Study Register
Back to Search Results. Study record. NCT04325061First Published: 2020 Apr 1Updated Date: 2021 May 4. Efficacy of Dexamethasone Treatment for Patients With ...
-
#4study protocol for a randomized controlled superiority trial.
This study will assess the role of dexamethasone in patients with established moderate-to-severe ARDS caused by SARS-CoV-2. ClinicalTrials.gov NCT04325061 .
-
#5Efficacy of Dexamethasone Treatment for ... - Cochrane Library
https://clinicaltrials.gov/show/NCT04325061, 2020 | added to CENTRAL: 30 April 2020 | 2020 Issue 04. Sourced from: CT.gov. Links: ClinicalTrials.gov.
-
#6Covid-19 Living Data
Trial NCT04325061 Publication Villar J, Unpublished, 2020 ( ) Funding: Public/non profit (Instituto de Salud Carlos III, Madrid, Spain(CB06/06/1088, ...
-
#7Efficacy of Dexamethasone Treatment for Patients With ARDS ...
Phase, Phase 4. Sponsor, Dr. Negrin University Hospital. Start date, April 2020. Enrollment, 19 participants. Identifiers, NCT04325061, 2020-001278-31 ...
-
#8nct04325061的情報與評價， 網路上有這樣的資料
以錢養錢，投資理財自己來！基金、股市、債券、外匯、期貨、高齡化金融商品、以及其他衍生性金融商品，各種資訊看這邊. 金融理財投資情報站 nct04325061. Search ...
-
#9(PDF) Efficacy of dexamethasone treatment for patients with ...
Trial registration: ClinicalTrials.gov NCT04325061. Registered on 25 March 2020 as DEXA-COVID19. Keywords: Acute respiratory distress ...
-
#10Association Between Administration of Systemic ...
The Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19 (DEXA-COVID 19; NCT04325061) trial and the COVID-19 ...
-
#11A Systematic Review and Meta-Analysis | SpringerLink
... NCT04325061); COVID STEROID (The hydrocortisone for COVID-19 and severe ... 23,24,25,26] (DEXA-COVID 19, NCT04325061; COVID STEROID, ...
-
#12Dexamethasone Terminated Phase 4 Trials for Coronavirus ...
Dexamethasone Terminated Phase 4 Trials for Coronavirus Disease 2019 (COVID‑19) / Acute Respiratory Distress Syndrome Caused by COVID-19 Treatment ; NCT04325061 ...
-
#13Interventions for treatment of COVID-19: second edition of a ...
Identifier NCT04325061: Efficacy of dexamethasone treatment for patients with ARDS caused by COVID-19 (DEXA-COVID19) Available at: ...
-
#14News: Insight into Dexamethasone's Benefits... (The Scientist)
... to mild respiratory tract illness to severe pneumonia, acute respiratory distress syndrome (ARDS), multiorgan failure, and death. The … NCT04325061.
-
#15Assessment of Evidence for COVID-19-Related Treatments
(NCT04325061) has been initiated to spe- cifically evaluate the use of dexamethasone in patients with ARDS due to COVID-19. 21.
-
#16Supplementary15RCTprotocols.docx - Research Square
[3] NCT04325061. Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19. 2020 : -. [4] NCT04327401. COVID-19-associated ARDS Treated ...
-
#17Supplementary Figure 1. Risk of Bias Summary for Each ...
NCT04325061. Glucosteroids. Control. 28-day mortality. 1. NCT04244591. NCT04244591. Glucosteroids. Control. 30-day mortality. 1. Jeronimo& Farias.
-
#18Efficacy of dexamethasone treatment for patients with the ...
... the role of dexamethasone in patients with established moderate-to-severe ARDS caused by SARS-CoV-2. TRIAL REGISTRATION ClinicalTrials.gov NCT04325061 .
-
#19Dexamethasone in severe COVID-19 infection: A case series
Available at: https://clinicaltrials.gov/ct2/show/NCT04325061?cond=Covid19+Dexamethasone&draw=2&rank=2, Accessed 11th Jul 2020.
-
#20Efficacy of dexamethasone treatment for patients with the ...
Trial registration: ClinicalTrials.gov NCT04325061. Registered on 25 March 2020 as DEXA-COVID19. Keywords: Acute respiratory distress syndrome, ...
-
#21Should dexamethasone be used for COVID-19?
NCT04325061 16. EudraCT 2020-. 001278-3117. (DEXA-. COVID19). MC^, OL, phIV, randomised, parallel assignment. Dexamethasone. Standard of care.
-
#22Dexamethasone Use in Coronavirus Disease COVID-19
Based on results of this study, a randomised controlled open -label trial (NCT04325061; DEXA-COVID19) initiated to specifically evaluate the use of IV ...
-
#23Therapeutics and COVID-19: living guideline - WHO | World ...
NCT04325061, accessed 31 August 2020). Website. 148. Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al.
-
#24Mario Negri Institute - Clinical Drug Experience Knowledgebase
NCT04325061. 2020. Trial Started. NCT04361916. 2020. Trial Started. NCT04361916. 2020. Trial Started. NCT04438850. 2020. Trial Started.
-
#25From Members of the American Heart Association - AHA ...
Treatment. Primary End Point. DEXA-COVID19 (Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19). NCT04325061. 60 d. Dexamethasone.
-
#26study protocol for a randomized controlled superiority trial ...
ClinicalTrials.gov NCT04325061 . Registered on 25 March 2020 as DEXA-COVID19. ... NCT 04325061. The study protocol (Version 1, 27 March 2020) was approved ...
-
#27Use of tocilizumab and sarilumab alone or in combination with ...
DEXA-COVID 19 (NCT04325061). COVID STEROID (NCT04348305). Steroids-SARI (NCT04244591). Tang_2 (NCT04273321). CoDEX (NCT04327401). Trial (trial registration).
-
#28Rafael Dal-Ré and Ignacio Mahillo-Fernández
NCT04325061. Dexamethasone. 200. 2-arm; parallel; open-label. Yes. No vs SOC. FJD-COVID19-20-01 2020-001262-11. NCT04392531. Ciclosporin.
-
#29The Impact of Corticosteroids on Secondary Infection and ...
(NCT04325061), CoDEX (NCT04327401), COVID STER-. OID (NCT04348305), and Steroids-SARI (NCT 04244591) intended to address secondary infection as an adverse ...
-
#30Supplementary appendix - The Lancet
NCT04325061. Dr. Negrin University Hospital. 2020-03-27 randomized, controlled, open-label trial. 6. Page 9. Methylprednisolone: 80 mg/d.
-
#31Supplementary Online Content - AMA Ed Hub
3. Missing outcome data. 4. Measurement of the outcome. 5. Selection of the reported result. Results for 28-day mortality. DEXA- COVID19 (NCT04325061).
-
#32Appendix 1: Summary - jstor
(NCT04325061). CoDEX. (NCT04327401). RECOVERY. (NCT04381936). CAPE-COVID. (NCT02517489). COVID. STEROID. (NCT04348305). REMAP-CAP. (NCT02735707).
-
#33Rafael Dal-Ré, Antonio J Carcas and Nadarajah Sreeharan ...
NCT04325061. DEXA-COVID 19. Spain / Dr Negrin University. Hospital. Dexamethasone vs SOC. 200. 2-arm; parallel; open-label /. Not yet recruiting.
-
#34CARING FOR THE CRITICALLY ILL PATIENT - Association ...
JAMA Published online September 2, 2020. E3. Table 1. Characteristics of Included Trials. Steroids-SARI². DEXA-COVID 19. NCT04325061. CODEX.
-
#35jama_sterne_2020_oi_200104_...
The Effi- cacy of Dexamethasone Treatment for Patients With ARDS. Caused by COVID-19 (DEXA-COVID 19; NCT04325061) trial and the COVID-19 Dexamethasone (CoDEX; ...
-
#36Pneumonies à SARS-CoV-2 - Infectiologie
DEXA-COVID 19 NCT04325061. 2.00 (0.21-18.69). 18.69. High: 20 mg/d intravenously. 69/128 76/128. CoDEX. NCT04327401. 0.80 (0.49-1.31).
-
#37Policy_Brief_002_Update_01.2021.pdf - AIHTA
(NCT04325061), which included small number of COVID-19 patients (from. 19 to 47), in comparisons to placebo or standard care.
-
#38Game of “crowning” season 8: RAS and reproductive ...
... such as methylprednisolone (NCT04263402; NCT04323592; NCT04244591), dexamethasone (NCT04263402; NCT04325061), budesonide, and formoterol (NCT04331470), ...
-
#39COVID‐19 pathogenesis, prognostic factors, and treatment ...
... NCT04273321, NCT04244591], dexamethasone [NCT04327401, NCT04325061] and budesonide [NCT04331470]) will confirm the positive results and ...
-
#40Immune Response and COVID-19: A mirror image of Sepsis
and NCT04325061. Methylprednisolone: NCT04329650 and NCT04343729. Prednisone: NCT04344288. Yes. Approved for several pathologies. Sirolimus.
-
#41Interventions for treatment of COVID-19 - PLOS
Identifier NCT04325061: Efficacy of dexametha- sone treatment for patients with ARDS caused by COVID-19 (DEXA-COVID19) Available at: https ...
-
#42Clinical Trials Sponsored by Dr. Negrin University Hospital
NCT04325061. Terminated. Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19. Conditions: Acute Respiratory Distress ...
-
#43Protocol and stat
https://clinicaltrials.gov/ct2/show/NCT04325061?term=COVID+and+dexa&draw=2&rank=1. 21. Community-Acquired Pneumonia : Evaluation of Corticosteroids ...
-
#44Prospective meta-analysis of randomized trials of ...
Azevedo & Bruno. Tomazini, Brazil. Efficacy of Dexamethasone. Treatment for Patients with. ARDS Caused by COVID-19. NCT04325061 Yes.
-
#45living meta-analysis of clinical studies - metaEvidence COVID ...
NCT04325061, RCT, dexamethasone, standard of care, COVID-19 severe or critically, low, 7/12, inconclusive, 90%. Steroids-SARI, 2020
-
#46The Molecular Basis of COVID-19 Pathogenesis ... - MDPI
Dexamethasone, Phase IV, Intravenous, Steroid drug to treat COVID-19 patients, NCT04325061. Favipiravir, Phase III, Oral, Antiviral drug to treat COVID-19 ...
-
#47Low‐dose hydrocortisone in patients with COVID‐19 and ...
40. Efficacy of Dexamethasone Treatment for Patients With ARDS. Caused by COVID-19 (DEXA-COVID19) (NCT04325061). https://clini caltr ials.gov/ct2/show/NCT04 ...
-
#48Terapia medicamentosa para infecções por coronavírus em ...
NCT04325061 Spain, Dexamethasone, Standard treatment, Phase 4, Recruitment, 27/03/2020, University Hospital Dr. Negrin. NCT04325633
-
#49Ciência & Saúde Coletiva - SciELO - Scientific Electronic ...
NCT04325061 Spain, Dexamethasone, Standard treatment, Phase 4, Recruitment, 27/03/2020, University Hospital Dr. Negrin. NCT04325633
-
#50Rationale for Prolonged Corticosteroid Treatment in the Acute ...
are in progress (NCT04273321, NCT04244591, NCT04325061, and NCT04323592) and results will not be available for months.
-
#5120219_WHO Living Guideline -Therapeutics and COVID-19
NCT04325061. 19. Spain. 60.7 68.4 Inpatient; NR. Critical (100%). 100. Dexamethasone (20 mg/day for 5 days, then 10 mg/day for 5.
-
#52a rapid systematic review. - Document - Gale Academic OneFile
... NCT04338958 Tofacitinib Germany Dexamethasone NCT04331665 Canada Naproxen NCT04332042 Italy Piclidenoson NCT04325061 Spain Camostat Mesylate NCT04325633 ...
-
#53COVID-19 Antiviral and Pharmacotherapy Information
37) Steroid clinical trials (NCT04244591, NCT04325061, and NCT04323592): https://clinicaltrials.gov/. 38) Stebbing J, et al.
-
#54Steroids for COVID-19 - First10EM
I will update this post as new trials are published. DEXA-COVID NCT04325061. Steroids-sARIO NCT04244591. COVID STEROID NCT04348305.
-
#55Therapeutic role of corticosteroids in COVID-19 - Future ...
Pneumonia. Proportion of patients requiring. ICU admission at any time within the study period. NCT04325061. Spain. Multi. April 2020 October.
-
#56Dexamethasone for the treatment of COVID-19 - EUnetHTA
NCT04325061. EudraCT 2020-. 001278-31. NCT04499313. Phase & Intention. Phase 2/3, to provide reliable estimates of the effect of study.
-
#57Tackling SARS-CoV-2: proposed targets and repurposed drugs
clinical trial for treating patients with ARDS caused by SARS-CoV-2 (ClinicalTrials.gov: NCT04325061) [115]. The efficacy of corticosteroid ...
-
#58the most prominent antiviral pharmaceuticals - SciELO Preprints
Actually, there are several clinical trials in recruiting phase (NCT04325061-. Spain; NCT04347980-France; NCT04395105-Argentina; ...
-
#59COVID-19 infection and glucocorticoids - Società Italiana di ...
NCT04325061 ) and budesonide (NCT04331470) alone or in combination with other therapies targeting inflamma-.
-
#60Comprehensive Summary of the Knowledge on COVID
NCT04325061 (ES). NCT04327401. (BR). NCT04344730 (FR). Inhibit excessive inflammation. A type of corticosteroid medication. Ciclesonide.
-
#61Corticosteroid therapy for severe COVID-19 pneumonia
< 1 mg/kg/day or equivalent. NCT04244591. NCT04263402. NCT04348305. Methylprednisolone. ≥ 1 mg/kg/day or equivalent. NCT04273321. NCT04343729. NCT04325061.
-
#62Should corticosteroids be used as an adjunct in the treatment ...
https://clinicaltrials.gov/ct2/show/NCT04325061?cond=COVID-19&draw=6&rank=44. 27. García F, Soriano A. Efficacy and Safety of Siltuximab vs.
-
#63Endothelial cells and blood vessels are major targets for ...
Dexamethasone, Immunosuppression against cytokine storm, 20 mg/d (5 d) then 10 mg/d (5 d), IV, NCT04325061.
-
#64Leidraad Corticosteroïden bij de behandeling van COVID-19
DEXA-COVID 19, clinicaltrials.gov identifier NCT04325061. REMAP-CAP, clinicaltrials.gov identifier NCT02735707. Ref: Angus DC, Berry S, ...
-
#65Repurposing anticancer drugs for COVID-19-induced ...
NCT04325061,. NCT04327401. Hydrocortisone Anti-inflammatory and immunosuppressive. Palliation of leukaemias and lymphomas. NCT04348305,.
-
#66Corticosteroides para COVID-19 - IRIS PAHO Home
(NCT04325061). CoDEX. (NCT04327401). RECOVERY. (NCT04381936). CAPE-COVID. (NCT02517489). COVID STEROID. (NCT04348305). REMAP-CAP.
-
#67Assessment of Evidence for COVID-19-Related Treatments
(NCT04325061) has been initiated to specifically evaluate the use of dexame- thasone in patients with ARDS due to. COVID-19. 21.
-
#68Mechanisms of action of repurposed drugs with potential activity
NCT04344730; NCT04325061] or methylprednisolone [NCT04374071;. NCT04355247; NCT04273321; NCT04343729] for moderate-severe. COVID-19 patients.
-
#69The hidden role of NLRP3 inflammasome in diabesity-related ...
Up to nowadays six clinical trials (NCT04347980, NCT04325061, NCT04395105, NCT04344730,. NCT04360876, NCT04327401), reported on ...
-
#70ASHP-COVID-19-Evidence-Table.pdf - SBMFC
-label trial (NCT04325061; DEXA-COVID19) has been initiated to specifically evaluate the use of IV dexamethasone at the same.
-
#71Understanding and Dealing the SARS-CoV-2 Infection
NCT04325061. Apr, 2020 to Oct, 2020. 11 Convalescent plasma. Immune- modulating. IV. III. NCT04372979. May, 2020 to May, 2021. NCT04343755.
-
#72WJV-9-27.pdf - NET
NCT04325061. Enoxaparin. Inhibition of Xa factor and thrombin 5. Not available. 4000 UI/d or 100 UI/kg. Subcutaneous injection.
-
#73COVID-19 Vaccine & Therapeutics Tracker - BioRender
Name ↓/↑ Technology ↓/↑ Stage ↓ Clinical Trial # Valsartan Other Phase IV NCT04335786; and 1 more Ebastine* Antivirals Phase IV ChiCTR2000030535 Danoprevir* Antivirals Phase IV NCT04291729
-
#7419: From Members of the American Heart Associa - Semantic ...
Treatment. Primary End Point. DEXA-COVID19 (Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19). NCT04325061. 60 d. Dexamethasone.
-
#75Nct04382053.
Несколько организаций: Другое: Фаза I / II / III / IV: NCT04325061 и Еще 25: Allocetra-OTS: Несколько организаций: Клеточная терапия: Фаза I / II: ...
-
#76Biochemical Pharmacology - art - torvergata
NCT04344730; NCT04325061] or methylprednisolone [NCT04374071;. NCT04355247; NCT04273321; NCT04343729] for moderate-severe.
-
#77Leidraad Corticosteroïden bij de behandeling van ... - NVALT
All seven studies (DEXA-COVID 19, NCT04325061; CoDEX, NCT04327401; RECOVERY, NCT04381936; CAPE. COVID, NCT02517489; COVID STEROID, NCT04348305; ...
-
#78Newborn Respiratory Distress Syndrome disease - MalaCards
47, Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19, Terminated, NCT04325061, Phase 4, Dexamethasone.
-
#79the COVID STEROID 2 trial - CRIC – Collaboration for ...
https://clinicaltrials.gov/ct2/show/NCT04325061?term=COVID+and+dexa&draw=2&rank=1. 26. Community-Acquired Pneumonia : Evaluation of ...
-
#80reporte breve nº 19 - uso de corticoides en el ... - EsSalud
ID: NCT04325061 - Efficacy of Dexamethasone Treatment for Patients With. ARDS Caused by COVID-19. Estudio registrado el 27 de marzo del 2020 ...
-
#81Dexamethasone (Hexadecadrol，地塞米松) - 仅供科研 - MCE
NCT04325061, Dr. Negrin University Hospital|Li Ka Shing Knowledge Institute|Consorcio Centro de Investigación Biomédica en Red, M.P..
-
#82covid_19_ 9_May_2020 - AACT Database
150, NCT04325061, Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19, DEXA-COVID19, 2020-001278-31 ...
-
#83COVID-19 HASTALARINDA KORTİKOSTEROİD TEDAVİSİ
(NCT04325061). CoDEX. (NCT04327401). RECOVERY. (NCT04381936). CAPE-COVID. (NCT02517489). COVID. STEROID. (NCT04348305). REMAP-CAP.
-
#84propecia post delivery - Discount and Cheap Prescription ...
... generally less likely in patients with ards caused by covid-19 dexa-covid 19; nct04325061 trial and the pet has kidney or liver disease, stomach ulcers, ...
-
#85RAS and reproductive hormones in COVID-19 – can we end ...
NCT04325061 ), budesonide, and formoterol. (NCT04331470), while there are no clinical trials evaluating reproductive hormones in COVID-19.
-
#86Prednisone problems - ComeUP Web Design
In bacterial sensitivity analysis of systemic candidiasis, nct04325061, we give advice. Fear paralyzes you have been conflicting standpoints, ...